Exclusive Report on Global Gene Therapy Market Analysis Report 2021 and Forecast to 2029 with different segments, Key players KSU | The Sentinel…

Global gene therapy market was valued at US$ 919.6 million in 2018 and is expected to reach US$ 5,609.9 million by 2027, growing at an estimated CAGR of 8.2% over the forecast period. The introduction of gene with the potential to cure or prevent the growth of a disease is termed as Gene Therapy. Increasing investment in research and development to discover lifesaving treatment for advanced diseases such as Cancer is driving the overall gene therapy market.

Gene therapy market is growing at a notable pace. Genetic or hereditary defects such as cardiovascular diseases, neurological disorders amongst others can be cured using gene therapy by introducing functional gene in the body and eliminating the defective ones. Gene therapy is categorized into somatic cell gene therapy and reproductive or germ line gene therapy. Gene therapy of Somatic cell are related to cells other than the germ cells or the reproductive cells while the germ line therapy are related to the reproductive cells with an objective to make changes to the hereditary factors to get the desired offspring. Somatic gene therapy can be further bifurcated into ex vivo gene therapy and in vivo gene therapy. In ex vivo gene therapy the cells are altered outside the body and the planted into the body while in the in vivo therapy cells are dealt inside the body. Somatic cell gene therapy is currently focusing on the treatment of tissue restricted disease such as Cystic Fibrosis, Adenosine Deaminase.

Get Sample Copy of this Report @

https://www.absolutemarketsinsights.com/request_sample.php?id=308

This market research report on the Global Gene Therapy Market is an all-inclusive study of the business sectors up-to-date outlines, industry enhancement drivers, and manacles. It provides market projections for the coming years. It contains an analysis of late augmentations in innovation, Porters five force model analysis and progressive profiles of hand-picked industry competitors. The report additionally formulates a survey of minor and full-scale factors charging for the new applicants in the market and the ones as of now in the market along with a systematic value chain exploration.

Top Key Players:

Some of the players operating in the gene therapy market are Voyager Therapeutics, Inc., Spark Therapeutics, Inc., Sangamo Therapeutics, Human Stem Cells Institute PJSC, Orchard Therapeutics plc, Genenta Science, Chiesi Farmaceutici S.p.A., Novartis AG, GlaxoSmithKline PLC, Gilead Sciences, Inc., Bristol Myers Squibb Delta Company Limited, Advanced Cell & Gene Therapy, LLC, Audentes Therapeutics, Inc., Biogen, and Pfizer Inc. amongst others.

Enquiry before Buying:

https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=308

The report answers important questions that companies may have when operating in the global Global Gene Therapy market. Some of the questions are given below:

What will be the size of the global Global Gene Therapy market in 2027? What is the current CAGR of the global Global Gene Therapy market? What products have the highest growth rates? Which application is projected to gain a lions share of the global Global Gene Therapy market? Which region is foretold to create the most number of opportunities in the global Global Gene Therapy market? Which are the top players currently operating in the global Global Gene Therapy market? How will the market situation change over the next few years? What are the common business tactics adopted by players? What is the growth outlook of the global Global Gene Therapy market?

Request For [emailprotected] https://www.absolutemarketsinsights.com/request_for_customization.php?id=308

About Us:

Absolute Markets Insights assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization.

From the in-depth analysis and segregation, we serve our clients to fulfill their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.

Contact Us:

Company: Absolute Markets Insights

Email id: [emailprotected]

Phone: +91-740-024-2424

Contact Name: Shreyas Tanna

The Work Lab,

Model Colony, Shivajinagar, Pune, MH, 411016

Website: https://www.absolutemarketsinsights.com/

Link:
Exclusive Report on Global Gene Therapy Market Analysis Report 2021 and Forecast to 2029 with different segments, Key players KSU | The Sentinel...

Transplant After CD19 CAR T-Cell Therapy Shows Durable Disease Control in Children, Young Adults With B-ALL – Cancer Network

In a long-term follow-up of an early-phase trial examining CD19.28 chimeric antigen receptor (CAR) T-cell therapy, the use of consolidative allogeneic hematopoietic stem cell transplant (alloHSCT) was associated with long-term and durable disease control in children and young adults with B-cell acute lymphoblastic leukemia (B-ALL).

These results were based on a cohort of 20 patients who were initially treated in a dose-escalation part of a phase 1 trial (NCT01593696) examining anti-CD19 CAR T-cell therapy in patients between 1 and 30 years who have not responded to standard treatment, plus an additional 30 patients who were treated in an expansion portion. The median follow-up for all patients examined was 4.8 years and represents the longest time period examined for the use of this therapy in children and young adults with B-ALL.

We demonstrate that CD19.28 CAR T cells followed by a consolidative alloHSCT can provide long-term durable disease control in [child and young adult patients] with relapsed or refractory B-ALL, wrote the study investigators who were led by Nirali N. Shah, MD. Following alloHSCT, we observed a significant long-term [event-free survival (EFS)] with an apparent plateau and a low relapse rate, providing support for this sequential approach for long-term cure.

The complete response rate (CR) was 62.0%, with 28 of the 31 patients achieving this end point also reaching minimal residual disease (MRD) negativity by flow cytometry. The rate of CR was higher in patients with primary refractory disease (P = .0035), fewer prior lines of therapy (P = .033), and an M1 marrow (P = .0007). Additionally, CR rates were better for patients who received fludarabine/cyclophosphamidebased lymphodepletion versus other regimens, at 69% and 25%, respectively (P = .041).

The median overall survival (OS) for the cohort was 10.5 months (95% CI, 6.3-29.2 months). The median EFS was 3.1 months (95% CI, 0.9-7.7), with rates at 3 and 6 months of 52.0% (95% CI, 37.4%-64.7%) and 38.0% (95% CI, 24.8%-51.1%), respectively. Notably, median EFS was not reached in patients treated with M1 marrow versus 0.9 months in those with M2 marrow (P .0001).

Of the patients achieving MRD-negative CR (n = 28), 21 (75.0%) went on to receive consolidative alloHSCT, with a median time to transplant of 54 days from infusion (range, 42-97). The median OS from transplant day 0 was 70.2 months (95% CI, 10.4 months-not estimable) and the median EFS was not reached. The rate of EFS at 5 years was 61.9% (95% CI, 38.1%-78.8%). There were 8 deaths between 0.8 and 71 months following alloHSCT, which included transplant-related complications and/or graft-versus-host disease or infection in 6 patients and 1 patient with a complication of secondary malignancy at 3 years post-transplant. Teo patients relapsed after alloHSCT, with a cumulative risk of relapse was 4.8% (95% CI, 0.3-20.3) and 9.5% (95% CI, 1.5%-26.8%) at 12 and 24 months, respectively, with death as a competing risk.

Of note, achieving a CR was associated with greater CAR T-cell expansion and grade 3/4 cytokine release syndrome (CRS). Overall, CRS occurred in 70.0% of patients, with 9 (18.0%) having a grade 3/4 event. Neurotoxicity occurred in 10 patients (20.0%), with 4 having severe neurotoxicity.

Central nervous system involvement was effectively treated with CAR T-cell therapy all patients with a marrow response and CRS, although 1 patients did have residual disease by flow cytometry at low levels.

The authors noted that given these findings, CD19-directed CAR T-cell therapy may be considered as a bridge to alloHSCT versus standard-of-care blinatumomab (Blincyto).

Despite its more ready availability, which is not dependent on manufacturing time or success thereof, the efficacy of blinatumomab in children is lower than in adults receiving blinatumomab and also lower than remission rates following CD19-CAR T cells, using any construct, particularly for those with high-burden disease, the study author wrote. Therefore, selection of CAR T cells over blinatumomab may be advantageous in patients with higher-burden disease and [extramedullary] disease or as a salvage for blinatumomab nonresponders.

References

Shah NN, Lee DW, Yates B, et al. Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL. J Clin Oncol. March 25, 2021. doi: 10.1200/JCO.20.02262

Read more:
Transplant After CD19 CAR T-Cell Therapy Shows Durable Disease Control in Children, Young Adults With B-ALL - Cancer Network

BioRestorative Therapies Announces Notice of Allowance for a New Patent Application Related to its Off-the-Shelf ThermoStem Program -…

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

MELVILLE, N.Y., March 31, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the Company) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the United States Patent Office has issued a notice of allowance for a patent application related to the Companys metabolic ThermoStem Program. The notice of allowance was issued on March 22, 2021 and is related to a new patent application not previously announced.

Claims granted under the new patent cover methodologies related to generating exosomes and brown adipocytes from human brown adipose-derived stem cells. Exosomes are small extracellular vesicles produced by cells that contain lipids, messenger-RNA, micro-RNA, cytokines and proteins. Therapeutic benefits of using exosomes have been demonstrated in various disease models and may provide a valuable therapeutic tool for treating disease.

We are pleased to see that we have been granted an additional patent by the USPTO for our ThermoStem Program, said Lance Alstodt, the Companys CEO. Our comprehensive portfolio of patents under our ThermoStem Program continues to expand as we develop and protect intellectual property related to large and growing markets where brown adipocyte therapeutics can be applied. Im very proud of our team, driving towards the achievement of our stated goals. The advancement of our technology is a core, fundamental value driver of our Company. Our family of intellectual property coupled with our financial reporting progress are critical factors contributing to our growth strategy.

It is expected that the exosome diagnostic and therapeutic market will reach $368 million by 2022 as the development of research, clinical tools and therapeutics continues to grow in this emerging technology.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

Disc/Spine Program (brtxDISC): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a persons own) cultured mesenchymal stem cells collected from the patients bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patients bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patients damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease.

Metabolic Program (ThermoStem): We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:Email: ir@biorestorative.com

More:
BioRestorative Therapies Announces Notice of Allowance for a New Patent Application Related to its Off-the-Shelf ThermoStem Program -...

Stem Cell Assay Market Changing Dynamics Of Competition With Forecast To 2030 The Bisouv Network – The Bisouv Network

Market Industry Reports (MIR) has published a new report titled Stem Cell Assay Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20192030. According to the report the global stem cell assay market was valued at over US$ 450.0 Mn. in 2017 and is anticipated to grow at a CAGR of 19.9% from 2019 to 2030.

The updated study released on Stem Cell Assay Market by Market Industry Reports is an ideal representation of all the ongoing happenings and activities in the market to help the manufacturers and the market player in planning crucial profitable strategies for the forecast period 2020 2030. The statistical research report presents recent industry insights, product analysis, historical data, and current information for offering a better market picture to the market players. Industry players can hence plan effective strategies for future and lead the market substantially. With higher profitability, market players can penetrate deeply in the Stem Cell Assay Market and ultimately emerge by implementing right strategies.

Get sample copy of Stem Cell Assay Market at: https://www.marketindustryreports.com/pdf/8

Some of the prominent players in the Stem Cell Assay Market include:

Thermo Fisher Scientific, Promega Corporation, STEMCELL Technologies Inc., Merck KGaA, GE Healthcare, Bio-Techne Corporation, Hemogenix, Bio-Rad Laboratories, Inc., Cellular Dynamics International Inc., and Cell Biolabs Inc.

Increasing global burden of diseases such as diabetes, cancer, and others are projected to be the major factors leading to the market growth. According to the World Health Organization (WHO) in 2017, number of patients suffering from type I and type II diabetes was estimated to be over 422 million. Moreover, the disease is expected to be the seventh largest cause of death by 2030.

According to American Cancer Society, in 2017, there were over 1.6 million new cancer cases in the U.S. Hence, there exists a need for developing new treatment methods which have led to the rise in approvals of clinical trials for the stem cell based therapies.

The Stem Cell Assay Market is segmented on the basis of Product, Modality, Cancer Type, End-Users and region.

by Product & Service (Instruments, Kits) Cell Type(Adult Stem Cells, Human Embryonic Stem Cells), Application (Regenerative Medicine, Drug Discovery, Clinical Research), Type (Cell Identification, Viability, Proliferation Assay)

Have any query? Inquiry about report: https://www.marketindustryreports.com/inquiry/8

The Research Report aims to resolve the following questions related to the Stem Cell Assay Market

Table of Contents

Buy this report @ https://www.marketindustryreports.com/checkout/8

About Market Industry Reports

Market Industry Reports is a global leader in market measurement & advisory services, Market Industry Reports is at the forefront of innovation to address the worldwide industry trends and opportunities. We identified the caliber of market dynamics & hence we excel in the areas of innovation and optimization, integrity, curiosity, customer and brand experience, and strategic business intelligence through our research.

We continue to pioneer state-of-the-art approach in research & analysis that makes complex world simpler to stay ahead of the curve. By nurturing the perception of genius and optimized market intelligence we bring proficient contingency to our clients in the evolving world of technologies, megatrends and industry convergence. We empower and inspire Vanguards to fuel and shape their business to build and grow world-class consumer products.

Contact Us-Email:[emailprotected] Phone:+ 91 8956767535 Website:https://www.marketindustryreports.com

See the original post here:
Stem Cell Assay Market Changing Dynamics Of Competition With Forecast To 2030 The Bisouv Network - The Bisouv Network

Top Executives from AveXis Join New Gene Therapy Venture — This Time Targeting Tens of Millions More Patients – PRNewswire

MADISON, Wis., March 29, 2021 /PRNewswire/ --A pair of top C-level Executives from blockbuster gene therapy company AveXis have joined ENDSULIN, a new venture that could reach millions more than any gene therapy to date. Spearheaded by one of the disease's most accomplished pioneers, the company aims to upend a multi-billion dollar treatment industry.

Both Brian Kaspar and Thomas Dee, the founding Chief Science and Chief Finance Officers, respectively, of AveXis (developer of Zolgensma, bought by Novartis for $8.7 Billionin May of 2018) have accepted board roles at ENDSULIN. While AveXis sought to "transform rare diseases," ENDSULIN is solely targeting one of the most prolific Type 1 diabetes (T1D) with what they hope will be a one-time treatment to free patients from daily insulin injections by more precisely regulating their glycemic control.

"The science itself is remarkable, but the potential to change millions of lives is unprecedented," Kaspar said. "We've proven gene therapy can revolutionize medicine with lasting, durable treatments. But now we need players like ENDSULIN with the right vision and focus who can harness that momentum to give patients the relief they deserve."

The former AveXis leaders round out a team of pioneering experts at the forefront of diabetes, gene therapy and drug development, strategically brought together to accelerate ENDSULIN's undivided focus: FDA authorization to begin human clinical trials.

Founder Hans Sollinger's previous discoveries have shaped modern pancreatic transplantation treatment for T1D. But because of the complexity of the disease, while the science of management has advanced, insulin shots have been the enduring standard of care since the 1920s almost a full century.

"25 years ago, I had performed more kidney-pancreas transplants than anyone in the world, but I'd only helped 500 people," Sollinger said. "The most important aspect of my search for a cure became its reach, in terms of both scale and accessibility. As I advanced, it became more and more obvious that gene therapy was the way to achieve it all, with no compromises."

Through decades of research at the UW Hospitals and Clinics, Sollinger's team developed a highly unique and targeted expression system that addresses one of the greatest challenges in treating T1D: precise regulation of insulin in response to rapidly fluctuating glucose levels. Several publications over the last 10 years have demonstratedlong-lasting euglycemia control in hundreds of mice and rats, indicating a durable cure may be within reach.

"We've focused everything we are doing around our mission to get this treatment to patients," said Eric Spyra, Interim CEO and Board Member. "Using existing commercial infrastructure and following the path of other liver-directed AAV gene therapies, we're putting all the pieces in place now that will accelerate this therapy through every stage."

ENDSULIN has already initiated a pilot study in autoimmune-modeled naturally diabetic companion dogs, while executing their IND-enabling plan and preclinical studies. The company is preparing for a Series A funding round this year.

ABOUT ENDSULIN ENDSULIN is reshaping the way we approach a cure for diabetes. They are working to free patients from daily injections and 24/7 management using the most cutting-edge gene therapy technology, developed from decades of research by noted diabetes leader Hans Sollinger, MD, PhD, Dr hc, at the University of Wisconsin Hospitals and Clinics. Their sole focus is to get a durable, one-time treatment to the millions of people who need it.

SOURCE ENDSULIN

http://www.endsulin.com

See more here:
Top Executives from AveXis Join New Gene Therapy Venture -- This Time Targeting Tens of Millions More Patients - PRNewswire

Gene Therapy for CNS Disorders Market 2021 Industry Size, Share, Growth and Top Companies Analysis- Gilead (Kite Pharma), Amgen (BioVex), Novartis,…

DataIntelo recently publishes an all-inclusive report on the Global Gene Therapy for CNS Disorders Market providing a complete overview of the key aspects of the market. Gene Therapy for CNS Disorders market report makes a robust assessment regarding the current market situation and its scope, which are anticipated to impact significantly on the performance of the market during the forecast period, 2020-2027. This report includes an in-depth analysis about the COVID-19 situation and its possible impact on the market in the next few years. The report contains XX pages, which provides a precise and detailed explanation of key components and their market expansion scope in the mentioned period. The key insights about the potential size, volume, and dynamics of the market as mentioned in the report is a vital guideline that would help clients to make informed decision about their business investment plans and strategies in the market.

As per the analysis, the global Gene Therapy for CNS Disorders market was valued at USD XX million in 2019 and is projected to reach a value of USD XX million by the end of 2027, expanding at a CAGR of XX% during the forecast period.

Few of the key players mentioned in this report:

Gilead (Kite Pharma) Amgen (BioVex) Novartis Roche (Spark Therapeutics) Bluebird Bio

Get FREE Exclusive PDF Sample Copy of This Report: https://dataintelo.com/request-sample/?reportId=113131

The report covers a detailed study on key areas such as market size, scope, and growth opportunities of the global Gene Therapy for CNS Disorders market by analyzing the market trend and data available for the period prior to 2019. From this analysis, the report draws several observations and deduces about the key factors that drive or restrain the market growth, which would have a wide impact on the development and expansion of the market during the forecast period. Moreover, it covers a range of opportunities and challenges prevailing in the market that will help clients to evaluate their investment strategies.

The global Gene Therapy for CNS Disorders market report examine the major segments and sub-segmentations of the market that are classified as the product types, applications, and regions. In additional to the harsh economic impact of the COVID-19 outbreak, the report studies the dynamics of the market by analysis the key performance of each segments and the potential expansion scope of the segments in the coming years. Furthermore, the scope of the growth potential, revenue growth, product range, and pricing factors related to the global Gene Therapy for CNS Disorders market in terms of applications are thoroughly assessed in the report in a view to entail a broader picture of the market.

The report, published by DataIntelo, is the most reliable information as the study consists of a concise graphical representations, tables, and figures which allow the users to easily understand the key market position of sectors or segment without going through a deep study of the report. The tables and figures represent the latest update information that provides a broad picture of several market developments of the products and services over the last few years.

Customize Report and Inquiry for the Gene Therapy for CNS Disorders market report @ https://dataintelo.com/enquiry-before-buying/?reportId=113131

The market report relies on a concrete research methodology focusing on both primary as well as secondary sources. The report is prepared by relying on primary source including interviews of the company executives & representatives and accessing official documents, websites, and press release of the private and public companies. Additionally, this report includes market analysis from several global experts and analysts who have in-depth knowledge about the market. To ensure a complete framework of the market, it also adopts several research tools such as statistical surveying for SWOT analysis, PESTLE analysis, predictive analysis, and real-time analytics.

Global Gene Therapy for CNS Disorders market by Products

Ex Vivo In Vivo

Global Gene Therapy for CNS Disorders market by Applications

Hospitals Clinics Others

You can buy the complete report in PDF format @ https://dataintelo.com/checkout/?reportId=113131

The report mentions some key global players in the market and additional names of the players in the market can be included as per the clients request. Moreover, a customized or separate report can also be available according to the needs of clients. The report covers the recent development of players including merger & acquisition agreements, partnership or joint venture and latest products launches from the key manufacturers in the Gene Therapy for CNS Disorders market. Please contact with our sales team, who will deliver reports that suits your necessities.

Competition Landscape

The report covers global aspect of the market, covering

North America Latin America Europe Asia Pacific Middle East and Africa

About DataIntelo:

DataIntelo is a globally leading distributor of market research report that has experienced by dealing with more than 800+ global clients. We offer quality market research report and provide data that can help generate a totally new approach for our clients to help change the outlook of their investment and business. Our mission is singular and well-defined we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473

Email:[emailprotected]

Website:https://dataintelo.com

See the original post:
Gene Therapy for CNS Disorders Market 2021 Industry Size, Share, Growth and Top Companies Analysis- Gilead (Kite Pharma), Amgen (BioVex), Novartis,...

Gene Therapy for Hemophilia Market will Reach Thriving Value by 2019 to 2028 SoccerNurds – SoccerNurds

A new research study titled Global Gene Therapy for Hemophilia market successfully portrays the entire global scenario as well as a detailed analysis of various regional segments.

Request Sample [emailprotected]https://insights10.com/free-sample-report-inquiry/?id=9158

The Gene Therapy for Hemophilia market research includes an examination of the leading geographies, such as North America (U.S., Canada), Europe (Germany, France, U.K., Spain, Italy, and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia, and Rest of Asia Pacific) Latin America ( Mexico, Brazil, Rest of Latin America) and Middle East & Africa (GCC countries, South Africa, and Rest of Middle East & Africa) for the period of 2019 to 2028.

The study on the Gene Therapy for Hemophilia market is a detailed review and presentation of the global industrys drivers, constraints, opportunities, demand factors, market size, historical data forecasts, and trends from 2019 to 2028. The study also assists in the comprehension of global Gene Therapy for Hemophilia market dynamics and structure by defining and evaluating market segments, as well as forecasting global market size.

Top Participants in the Gene Therapy for Hemophilia Market

F. Hoffmann-La Roche AG, Pfizer Inc., BioMarin Pharmaceuticals, uniQure and, Shire PLC.

Global Gene Therapy for Hemophilia Market Segmentation

A. By Class

I. Viral Vector II. Non-Viral Vector

B. Distribution Channel

I. Hospital Pharmacies II. Clinics III. Others

C. Geography

I. North America Market Analysis II. Europe Market Analysis III. Asia-Pacific Market Analysis IV. Middle-East and Africa Market Analysis

View Detail [emailprotected]https://insights10.com/product/global-gene-therapy-hemophilia-market/

Table Of Content of Global Gene Therapy for Hemophilia Market

1. Global Gene Therapy for Hemophilia Market Overview. A. Market Size 2. Market Growth Drivers.. A. Rise in Global Prevalence of Gene Therapy for Hemophilia B. Growing R&D Investments and Reimbursement Policies 3. Gene Therapy for Hemophilia Market Segmentation. A. By Class I. Viral Vector II. Non-Viral Vector B. Distribution Channel I. Hospital Pharmacies II. Clinics III. Others C. Geography I. North America Market Analysis II. Europe Market Analysis III. Asia-Pacific Market Analysis IV. Middle-East and Africa Market Analysis 4. Gene Therapy for Hemophilia Disease Major Market Share.. A. Market Analysis, Insights and Forecast By Revenue 5. Competitive Landscape. A. Major Players B. Products in Pipeline 6. Key Company Profiles A. Pfizer overview, Product & Services, Strategies & Financials B. Shire PLC Company overview, Product & Services, Strategies & Financials C. Roche Company, Product & Services, Strategies & Financials 7. Healthcare Policies and Regulatory Landscape. A. Policy changes and Reimbursement scenario 8. Factors Driving Future Growth.. A. New Trends and Development of Gene Therapy for Hemophilia market B. Future Opportunities 9. Barriers in Future Growth. 10. Conclusion

The report also looks at key players competitive environment in terms of product, value, financial situation, product portfolio, growth strategy, and regional presence. The study includes a value chain analysis and a SWOT analysis to address the issue of whether shareholders should concentrate their efforts and investments in the near future on the Gene Therapy for Hemophilia markets emerging segment. Furthermore, the report is a collective presentation of primary and secondary research findings.

Buy [emailprotected]https://insights10.com/checkout/

Contact:

Email :[emailprotected]

ContactNumber :+91 79 4009 3656

Continue reading here:
Gene Therapy for Hemophilia Market will Reach Thriving Value by 2019 to 2028 SoccerNurds - SoccerNurds

Global Automated and Closed Cell Therapy Processing Systems Market Trends and Forecasts, 2020-2030: Cell Processing Steps, Scale of Operations, End…

Dublin, April 01, 2021 (GLOBE NEWSWIRE) -- The "Automated and Closed Cell Therapy Processing Systems Market By Cell Processing Steps, Scale of Operations, End Users and Geographical Regions: Industry Trends and Global Forecasts, 2020 - 2030" report has been added to ResearchAndMarkets.com's offering.

The "Automated and Closed Cell Therapy Processing Systems Market: Focus on Apheresis, Expansion, Harvest, Fill/Finish, Cryopreservation, Thawing, 2020-2030" report features an extensive study of the current market landscape and future opportunities associated with the automated and closed cell therapy processing systems. The study also features a detailed analysis of key drivers and trends related to this evolving domain.

One of the key objectives of the report was to estimate the existing market size and the future growth potential of the automated and closed cell therapy processing systems. Based on various parameters, such as number of cell therapies under development, expected pricing, likely adoption rates, and potential cost saving opportunities from different automated and closed cell processing systems, we have developed informed estimates of the evolution of the market, over the period 2020-2030.

Advanced therapy medicinal products (ATMPs), such as cell therapies and gene therapies, have revolutionized the healthcare sector. Over the past two decades, more than 30 ATMPs have been approved. Moreover, according to a recent report (published by The Alliance for Regenerative Medicine), over 1,050 clinical trials are currently being conducted by over 1,000 companies, worldwide, focused on the evaluation of cell and gene therapies.

However, despite the numerous advances in this field, there are certain challenges that need to be addressed in order to achieve commercial success. For instance, the current cell therapy manufacturing process is labor-intensive, time consuming and costly. Further, the production of most of these specialized therapeutic products requires manual labor and are typically carried out discretely (open processing), thereby, rendering the processes difficult to scale-up, with high risk of contamination.

Another concern faced by cell and gene therapy manufacturers is batch-to-batch variability, given that even a minor change in the production protocol can affect the quality of the resulting product. Consequently, cell therapies are exorbitantly priced, ranging from USD 300,000 to USD 500,000 per dose.

Experts believe that some of the existing challenges related to cell therapy manufacturing can be addressed through the adoption of automated and closed cell processing systems. These solutions have been demonstrated to be capable of enabling stakeholders to manage various aspects of the cell therapy manufacturing process efficiently, while complying to global regulatory standards. Other benefits of such systems include reduced risk of contamination, optimum utilization of facility and resources, limited in-process variation and consistent product quality.

Further, the use of such automated systems enable significant reductions (in the range of 40% to 90%) in labor costs. In recent years, the cost saving potential of these systems, coupled to their ability to streamline and simplify the complex cell therapy processing (from initial cell collection till final formulation), has effectively captured the interest of several stakeholders engaged in this domain. Given the growing demand for cost-effective, personalized medicine, coupled to the benefits of automated and closed systems, we believe that this niche market is poised to witness significant growth in the foreseen future.

Scope of the Report

An insightful product competitiveness analysis, taking into consideration various relevant parameters, such as supplier power (based on the experience/expertise of the developer in this industry) and portfolio-related parameters, such as number of systems offered, cells supported, type of culture supported, scale of operation, applications, end users, support services offered, regulatory certifications/accreditations obtained and key product specifications.

Elaborate profiles of industry players that are currently offering automated and closed cell therapy processing systems, featuring an overview of the company, its financial information (if available), and a detailed description of the system(s) they offer. Each profile also includes a list of recent developments, highlighting the key achievements, partnership activity, and the likely strategies that may be adopted by these players to fuel growth, in the foreseen future.

An analysis of the various partnerships pertaining to automated and closed cell therapy processing systems, which have been established since 2016, based on several parameters, such as year of partnership, type of partnership model adopted, type of therapy, type of cell processing step, key automated and closed cell processing systems, partner's focus area, most active players (in terms of number of partnerships signed), and geographical location of collaborators.

A detailed assessment of the current market landscape, featuring an elaborate list of over 60 automated and closed systems, along with information on the cell therapy processing step for which they are designed (apheresis, separation, expansion, harvest, fill/finish, cryopreservation and thawing), their key features (traceability, user-friendliness, configurability and scalability, process monitoring, touch-screen user interface, data management, integration with other systems and alert system), product specifications (length, width, depth, height and weight), type of cells supported (stem cells and immune cells), type of cell culture (adherent and suspension), scale of operation (pre-clinical, clinical and commercial), application (research and therapeutic), end users (hospitals/medical centers/clinics, research institutes/academic institutes, laboratories, commercial organizations), key support services offered (product support, technical support, training, installation, qualification/validation, maintenance, regulatory support and others) and regulatory certification/accreditations obtained (GMP/cGMP, GAMP, GCP, GTP/cGTP, IEC standards, ISO standards, 21 CFR Part 11 and other).

The report features detailed transcripts of interviews held with the following industry stakeholders:

Key Questions Answered

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/ly01kj

Read more:
Global Automated and Closed Cell Therapy Processing Systems Market Trends and Forecasts, 2020-2030: Cell Processing Steps, Scale of Operations, End...

Hair Restoration Market Size Worth $13.6 Billion By 2028 | CAGR: 15.4%: Grand View Research, Inc. – PRNewswire

SAN FRANCISCO, March 31, 2021 /PRNewswire/ -- The global hair restoration marketsize is anticipated to reach USD 13.6 billion by 2028, according to the new report of Grand View Research, Inc. The market is expected to expand at a CAGR of 15.4% from 2021 to2028. Hair restoration technique which includes surgical as well as a non-invasive treatment option is an effective procedure to increase hair thickness, fill in a receding hairline, and treat baldness as well as severe alopecia. According to the American Academy of Dermatology, androgenic alopecia is the most common cause of hair loss in both men and women. According to the American Hair Loss Association, 95 % of hair loss in men is caused by androgenetic alopecia and around 40% of men notice symptoms of baldness by the age of 40.

Key suggestions from the report:

Read 107 page research report with ToC on "Hair Restoration Market Size, Share & Trends Analysis Report By Procedure (Follicular Unit Extraction, Follicular Unit Transplantation), By Therapy (Low-level Laser Therapy, Stem Cell Hair Restoration, Platelet-rich Plasma), And Segment Forecasts, 2021 - 2028" at : https://www.grandviewresearch.com/industry-analysis/hair-restoration-market

The market is currently witnessing a surge in treatment adoption due to high psychological stress, poor dietary habits, reduced nutritional levels with age progression, and increasing hormonal changes due to lifestyle shifts among the global population. This surge can also be due to the increased success rate of the transplantation procedures and technological advancement in the field of less invasive hair repair.

In the light of COVID-19, the market was hampered as the footfall of patient appointments for surgical Follicular Unit Extraction (FUE) or Follicular Unit Transplantation (FUT) treatments was temporarily suspended. However since the government in many countries has allowed resuming elective surgical procedures, clinics have also started hair transplant procedures again and international organizations like the International Society of Hair Restoration Surgery (ISHRS) has set strict protocols for resuming hair restoration practices as well as offer patient guidance in finding hair repair clinics deemed.

Grand View Research has segmented the global hair restoration market on the basis of procedure, therapy, and region:

List of Key Players of Hair Restoration Market

Find more research reports on Medical Devices Industry,by Grand View Research:

Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James Corporate Sales Specialist, USA Grand View Research, Inc. Phone: +1-415-349-0058 Toll Free: 1-888-202-9519 Email: [emailprotected] Web: https://www.grandviewresearch.com Follow Us: LinkedIn| Twitter

SOURCE Grand View Research, Inc.

View post:
Hair Restoration Market Size Worth $13.6 Billion By 2028 | CAGR: 15.4%: Grand View Research, Inc. - PRNewswire

How Aviv Clinics in Florida’s The Villages Retirement Community Fights Aging – menshealth.com

Its 5:30 p.m. on a Tuesday, and happy hour has begun at Brownwood Paddock Square inside the Villages, a 55-plus active--retirement community in Florida. Gray-haired couples amble along the sidewalks of the early-1800s-western-themed town center, toting folding chairs and cooler s. A band is playing Blue Suede Shoes in the corral. Maskless throngs in windbreakers and visors shuffle out of the restaurants and bars, scoping out the best spots for the concert. Customized golf cartsfuchsia, blaze orangeline the curb, glimmering in the light of the setting sun.

In the past, I would have smiled condescendingly at this scene. (Aw, look at these oldsters rocking out on their new knees!) Instead, I drink it in, pondering my own mortality. Im 55officially old enough to live at the Villagesand am here to visit the new Aviv Clinics, which offers a compelling and potentially game-changing therapy to combat the effects of aging.

Rhona Wise/AFP via Getty Images

The Villages is a location, but its also a concept: a place where the almost old, and the actually old, go to feel less old. Its where you can act young without being young, and its where an estimated 132,000 people (and countingthe metro area has one of the fastest growth rates in the country) are testing the hypothesis that feeling young is more a mindset than a number. There are 50 golf courses and more than 3,000 clubs and activities, from karate to knitting. It may seem counterintuitive, but this city/club/social experiment may offer a glimpse of the future. Your future, specifically.

Americans are an aging population for the obvious reasons. Medical breakthroughs mean more of us live longer, and the surge of baby boomers born after World War II are hitting their senior years. By 2030, one in five adults will be at least 65, according to the U.S. Census Bureau. With the power of numbers, this 65-plus crowd is changing how we think about growing old, challenging the convention that seniors should rest and take things easy.

EVE EDELHEIT/The New York Times/Redux

People often compare the Villages to Disney World, given the themed town centers. But Glenn Colarossi, the head of Avivs business development and my host, likens it to a college campus for the retired. They like to have fun, he observes. The Villages is reimagining our notion of the golden years, and Aviv is greasing the wheelsand jointsof this revolution. Its goal, Colarossi tells me, is to increase a persons health span, not just their life span.

Men's Health

Pioneered by Israeli physician Shai Efrati, M.D., the clinic studies each client down to their DNA and constructs a personalized plan for staying physically and mentally healthy. The centerpiece is hyperbaric oxygen therapy (HBOT), in which patients breathe pure oxygen at varying pressures in a hyperbaric chamber, potentially inducing cell growth and expanding blood vessels in the brain. The original research center in Israel opened 15 years ago, and the Florida site opened in March 2020. If I were entering the 12-week program, Id meet with a physical therapist, a physiologist, a doctor, and a dietitian; engage with millions of dollars worth of machinery; and submit DNA, which would result in a 200-page book of codes and genetic indicators that each of the experts would parse. There would be 60 sessions in the hyperbaric chamber as well as before-and-after MRI and SPECT brain scans. The program cost: $45,000. Is this just another get-young-quick fad for the rich and yet another reminder of our health-care systems inequalities? Or do HBOT and a customized evaluation of your physiology offer some chance to counteract declining brain and body function and help in the fight we all eventually fightthe one against aging?

Bob Croslin

The Aviv lobby where I check in is a cavernous expanse of white tile and polished wood. The overhead lights double as sculptures. It is celestially sleek. If the designers were going for a Gods-waiting-room vibe, they nailed it. Im scheduled for a sample of the three-day assessment, condensed into two days. I dont feel or even think of myself as old. I run regularly with my wife and take boxing classes with my oldest. The other day, when I barked at my teenage daughter to get off the phone and do the dishes, she muttered, Grumpy old man. We locked eyes...and laughed. Funny because it was so not true. But I do have persistent lower-back pain, and odds are 50-50 I get up in the middle of the night to pee. Then theres the looming shadow of declining brain function, which for someone who lost his father to Alzheimers is too terrifying to joke about.

My first evaluation will determine my physical and cardiopulmonary state. I meet with Ankita Shukla, D.P.T., a trim, sharp woman who runs me through a gauntlet of tests to measure the flexion, extension, rotation, and abduction of every joint in my body, zeroing in on the limited range of motion in my neck and back...and (sigh) knees, wrists, and hips.

Bob Croslin

In one test, to assess my dual-task ability, she asks me to briskly walk to a cone while counting down from 100, subtracting each number by three. I utter only two numbers, one of which is right. On my second attempt, I actually count forward, not backward. She recommends a serious stretching regimen for my body, neck, hips, and wrists. For posture, she offers a quick cheat: stand with my back against a wall for more than a minute at intervals throughout the day. To increase my dual tasking, she suggests I count backwardnumbers, months, the alphabetduring my workouts.

Shukla hands me off to physiologist Aaron Tribby, a fit young man who is a body-movement specialist. Tribby straps me into the Gaitway 3D, a biomechanics treadmill that measures my gait and step pressure to check my coordination and see if Im losing functionality. I have some foot rotation, which might be caused by tight hip flexors, taut hamstrings, or rigid ankles. He gives me exercises to remedy all three.

Bob Croslin

Next, I visit Roger Miller, Ph.D., Avivs charming clinical psychologist. Ive got the best job here, because everything is controlled by the brain, he proclaims with a smile. Im going to tell you five words, he instructs. I want you to repeat them to me. I ace it. Then I take a battery of increasingly difficult cognitive tests: the written Montreal Cognitive Assessment, or MoCA (at the end of this test, he asks me to recite the five words again; I dont ace it); the NeuroTrax, to assess functions like memory, attention, and problem-solving; the CANTAB, which looks at processing speed, flexible thinking, and spatial memory. The results: You showed comparative strengths in your nonverbal memory, fine motor speed and coordination, and executive-function skills. And in a sentence ripped right from my wifes playbook: There were relative weaknesses in your information-processing speed and sustained attention.

None of the testing so far is super cutting-edge, and the advice, while sound, is mostly stuff I knew I should be doing. I then meet with Mohammed Elamir, M.D., the lead physician at Aviv who runs point on interpreting all the data from the team, including from specialized brain scans that track blood flow in the brain and identify diminished zones, to gain a holistic view of how a patient is aging. I didnt get the brain scans, so Dr. Elamir gives me a basic neuroscience history lesson, which like everything else at Aviv traces back to its cofounder Dr. Efrati. Dr. Elamir tells me he was drawn to Aviv because he came across research by Dr. Efrati that indicated that central-nervous--system cells in the brain could regenerate and rejuvenate. That is not what we were taught in medical school, he says. This was not deemed feasible. Now, he says, thanks to Dr. Efratis HBOT research, there is preliminary evidence they can.

Bob Croslin

Dr. Efrati is a professor at the Sackler School of Medicine at Tel Aviv University and the founder and director of the Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center. He has been studying the effects of hyperbaric oxygen therapy for more than 20 years, he tells me on a Zoom call. Hes 50, with close-cropped gray hair and a warm, TED-talk-polished bedside manner. Dr. Efrati says he developed an interest when a stroke patient with an ulcerated leg wound was put in a hyperbaric chamberan accepted wound therapy. After a series of treatments, he noticed the womans neurological disabilities were improving as well. This led him to investigate the regenerative effects of HBOT on the brain. He discovered in 2007 that, indeed, neurons and blood vessels in the brain can be regenerated.

The apotheosis of his work was identifying a phenomenon called the hyperoxic--hypoxic paradox. By manipulating levels of oxygen in the chamber, you can essentially fool the body into perceiving that its being starved of oxygen, a state called hypoxia, without harmful side effects. During the hyperoxic stage, oxygen floods the cells. According to Dr. Efrati, this can promote the production of stem cells, valuable because they can develop into most any cell in the body. The treatment can also promote the branching of new blood vessels into areas of the brain damaged by events like strokes.

Bob Croslin

Dr. Efrati started treating stroke patients with HBOT in 2007, then brain--trauma patients in 2008. Today, he works with people who want to remain physically and mentally active. About five years ago, we decide we move forward with targeting aging as a disease, he says.

Dr. Efratis recent research results are intriguing. Notably, a November 2020 clinical trial of 35 people ages 64 and older indicates that HBOT can increase the length of telomeres, the area of specialized protein at the ends of chromosomes. (Telomere shortening is a sign of aging.) Another of his clinical trials published last June, of 63 patients, found evidence of cognitive enhancement in adults ages 64 and older after HBOT. The specific benefits were increased cerebral blood flow resulting in improvement in executive function, information--processing speed, and attention.

However, there is skepticism in the wider medical community. Usually, small clinical studies would be followed by larger, multicenter, randomized clinical trials, says James E. Galvin, M.D., M.P.H., a professor of neurology and the director of the Comprehensive Center for Brain Health at the University of Miami. This has not happened with HBOT yet. Dr. Galvin, who is engaged in dementia--prevention-and-therapy research, is familiar with Dr. Efratis work. I think one should be cautious about overinterpreting results from very small studies performed at single sites with very small effects, he says. Im not discounting the research. Theres just not a lot of research on HBOT use in patients with various forms of dementia. He adds that the majority of studies appear to be on only one type of dementia: vascular. Im cautious about rushing treatments for broad commercial use before the research shows its effective.

Bob Croslin

Even though HBOT therapy is new, I see about 20 other patients during my visit, mostly couples, in their 70s and 80s. (Aviv declined to reveal patient data.) Im reminded of something Dr. Elamir told me: The motivation for treatment he hears most from patients is not wanting to be a burden on their partner when cognitive decline, dementia, or stroke makes them less independent. One patient I talk to, Elliot Sussman, M.D., is the chairman of the Villages Health health-care provider. Dr. Sussman, 69, is 45 diveswhat they call sessions in the hyperbaric chamberinto the program. Even though the preprogram MRI of his brain was normal, his goal, he says, is to sharpen his cognitive function. But the most notable effect for him has been a significant increased need for sleep, he says, an additional hour or more every night. This is good news, the doctors told him, a sign his brain is regenerating and repairing, in the same way babies need sleep to aid development of their growing brains. It may seem underwhelming, but Dr. Sussman feels the investment will pay off.

After a night observing the Villages frenetic social scene, Im up early the next morning to meet registered dietitian Kathryn Parker, a cheery woman with flowing gray hair. She has me stand on the Seca Medical Body Composition Analyzer and grip the handles. Within minutes, a report is compiled that assesses my water composition (good, at 58 percent), my visceral adipose tissue (fat around my organs, which is very good, at 1.9 on a chart that goes to 5), and a host of other things, including skeletal muscle mass (which at 63 pounds for my 167-pound body is okay; she wants it to be between 64 and 84). Im losing muscle mass as I age, and Ill need it to keep from falling down when Im actually old. She suggests I do more strength training and eat more protein daily. (MH advises eating about one gram of protein per pound of your target weight each day.) Parker likes nutrients to come from food (rather than supplements) and recommends snacks of yogurt, cheese, and whey-powder shakes. Its refreshingly straightforward nutrition advice.

Then Im back with physiologist Tribby for a spirometry and VO2-max stress test. He tapes on ten electrodes for the ECG, straps a mask over my head, and puts me on a treadmill. As both speed and incline gradually increase, Im instructed to run until I just cant go anymore, whatever that means. Nine minutes later, I find out. The ensuing report shows that my lung efficiency, including the amount of air I take in and forcibly exhale, is normal for my age and gender. At 34 kg/min, my max oxygen intake during intense exercise is a little better than average for my age. But before this goes to my head, Tribby points out that elite athletes test more than double that. My report is five pages of mediocrity, challenging my self-image as fit. To improve my fitness, he recommends standard stuff: exercise three or four days a week at 70 to 80 percent of my max heart rate, which is 165 bpm. I also need to work in a couple sessions of HIIT and one endurance workout.

Bob Croslin

Finally, Im ready for my dive. The chamber is designed like an airplanes first-class compartments to combat the claustrophobia some may feel and because it looks cool. I wear a mask to breathe the oxygen and sit in a very comfortable chair for an hour, half a regular session. The scheduled air and oxygen intervals at pressure induce the hyperoxic--hypoxic paradox. My breaths through the mask are slightly easier than breathing through a scuba regulator, but Im conscious of every inhale and draw the air deep into my lungs. My one session wont have a measurable effect on my brain, but I get the idea. When I emerge, Im light--headed. That night, I sleep deeply, my brain awash, presumably, in increased O2.

My two days give me only a glimpse inside the Aviv process. The data I get from my biometric measurements puts me in a good placeno immediate evidence that my body is aging faster than my brain, or vice versa, just that I am inexorably getting older. This one-stop mind-body checkup has taught me that (a) its great to have access to a team of medical experts under one roof and (b) I need to adhere to health and antiaging best practices, now more than ever. Physically Im inspired to do more stretching, improve my posture, up the exercise intensity, and eat more protein. I might even take up knitting to stay sharp. My exposure to the Villages has challenged me to look unflinchingly at the future and play and prepare for the long game.

More than anything, Im relieved there were no cognitive red flags. I couldnt afford the $45,000 price tag to potentially reverse a brain problem. Hopefully the science behind HBOT will be proved effective and the cost will come down. Until then, the prospect that age-related cognitive decline can be staved off gives me optimism that Ill stay active long enough to keep that smirk off my daughters face for decades to come.

This story appears in the May 2021 issue of Men's Health with the headline Where Aging Goes To Die.

Original post:
How Aviv Clinics in Florida's The Villages Retirement Community Fights Aging - menshealth.com